<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867203</url>
  </required_header>
  <id_info>
    <org_study_id>CYPstatin001</org_study_id>
    <nct_id>NCT01867203</nct_id>
  </id_info>
  <brief_title>Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy</brief_title>
  <official_title>Lipid-lowering Therapy Individualization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients needing lipid lowering therapy will be recruited before initiation of the treatment.
      For each patient, total and LDL cholesterol levels before start of therapy will be measured.
      One, three and six months after his/her first visit, when steady-state will be reached, for
      each included patient, the cholesterol levels will be re-assessed in order to evaluate the
      response to statin therapy calculated as the amplitude of cholesterol reduction. The aim is
      to assess the association between patient's genotype and the response to statin therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Cholesterol levels-side effects</measure>
    <time_frame>1 to 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Patients With High Cholesterol Levels Needing a Lipid-lowering Therapy</condition>
  <arm_group>
    <arm_group_label>Statin users</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Genotyping</intervention_name>
    <description>DNA extraction from blood</description>
    <arm_group_label>Statin users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with statin drugs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient known to be compliant

          -  Age [25-80]

          -  treated with Atorvastatin, simvastatin, fluvastatin.

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laure Elens, PhD</last_name>
    <phone>+32 764 5351</phone>
    <email>laure.elens@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint-Luc Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haufroid Vincent, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laure Elens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>May 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2013</study_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

